No kidding! This is great news event! Show's her confidence in the company and in it's near and long term outlook!
Also, interesting tid bit is that she reported it earlier than required by Rule 16b-3. Humm.......Like they say "timing is everything" you know!!!
I think you are correct.....Looks like OMB! OMB Approval - OMB # 3235-0287, Total shares 25,000 of which 4.774 shares were purchased from her 401k proceeds. You go girl!
You are full of #$%&........Stop trying to get investors to part with their shares. You and your hedge fund buddies need to GO AWAY!!!!!
Investors beware of posters on this MB! Know those you can actually TRUST!
Seriously? You want to talk about convertible debt obligations due in 2019? ....7 years out? Seriously? On this company? I don't see this as a concern at all! Drop in the bucket to where I see EXEL by then!
We are on the same page Duck! It get's really old trying to look through the MB trying to take part in the conversations with people who are actually INTERESTED in this companies future and the advancement in care they have for patients in need.
Enjoy conversations about the science, ongoing trials, and the HUGE potential of this company!
I have had you in my thoughts of late because I had not seen many recent posts from you and was concerned.....I hope all is well with you. I am a fairly newcomer on this MB of EXEL (and long) and just wanted you to know how much I have enjoyed your informational posts and wisdom.
Good to hear from you and wishing you a most blessed of holiday season!
Where did you get the information about a possible interim report on Comet 1? Just wondering,,,,,looking forward to the data results.
Let me point you to where I had read that information about early data release on Comet 1. If you go to the recent headlines under Yahoo, date of November 29, look at the article titled "Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development at Seeking Alpha (Thu, Nov 29). It is written by George Dimopoulos, Ph.D., and Ning Yang, Ph.D..
I should have stated though, that the Comet 1 is "currently enrolling" and not "enrolled". My apologies. That is important and was an oversight on my part.
I guess I got caught up in the excitement of approval and had remembered reading this and wanting to share........And also, by the way, I am on the same side of the line as you, Ernie, Duck, Chem, and OncoDoc and respect all of your posts and insights on EXEL.
It's my understanding that it's the Comet 2, Phase III trail, that will report mid 2014.
On that trial, Comet 2, it is focused on men with previously treated, symptomatic mCRPC. Patients will be given either cabozantinib (60mg qd) or intravenous mitoxantrone (q3 weeks) with prednisone (5mg bid). The primary endpoint of the trial is pain response and secondary endpoints include overall survival AND bone scan response.
I think I'm on target with this.......